The QualityStocks Daily Wednesday, September 18th, 2019

Today's Top 3 Investment Newsletters

Stock Guru (ZIMCF) +358.22%

BUYINS.NET (SPI) +66.37%

QualityStocks (BLXX) +63.93%

The QualityStocks Daily Stock List

Bionik Laboratories Corp. (BNKL)

NetworkNewsWire, Zacks, Stockhouse, Wallet Investor, InvestorsHub, Equities, MarketWatch, Real Investment Advice, TradingView, Market Screener, MarketBeat, Business Insider, Business Wire, Barchart, Last10k, and 4-Traders reported earlier on Bionik Laboratories Corp. (BNKL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Bionik Laboratories Corp. centers on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home. A robotics company, Bionik has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients. This includes three products on the market and four products in varied stages of development. OTCQB-listed, Bionik Laboratories is based in Toronto, Ontario.

Resulting from pioneering research at the Newman Laboratory for Biomechanics and Human Rehabilitation at the Massachusetts Institute of Technology (MIT), the InMotion Robots provide effective, patient-adaptive therapy, intended to restore upper-extremity motor control for a wide variety of neurological conditions and recovery stages. This includes early recovery from acute stroke. Additionally, InMotion Robots provide objective evaluation assessments intended to measure and report the patient’s level of motor impairment and progress during the course of therapy. A home version of the InMotion upper-extremity technology is undergoing development.

Bionik Laboratories has commercially launched its newest generation InMotion ARM/HAND™ robotic system for clinical rehabilitation of stroke survivors and those with mobility impairments because of neurological conditions. Bionik has completed the transition to outsourcing of the production of the newest generation InMotion ARM/HAND™ robotic system, and the InMotion ARM™, to its manufacturing partner Cogmedix, in Massachusetts. Bionik is continuing the development of a lower-limb assistive exoskeleton for individuals with impaired mobility through an earlier announced manufacturing partnership with Wistron Corporation.

Bionik Laboratories announced this past May the completion of a landmark Robot Assisted Training for the Upper Limb after Stroke (RATULS) trial utilizing its InMotion Robotic Therapy Systems. Results of the RATULS trial were presented at the European Stroke Organisation Conference (ESOC) in Milan, Italy on May 22, 2019. They were published in the Lancet Online Journal on the same day. The purpose of the study was to compare clinical effectiveness of robot assisted training, enhanced upper limb therapy, and usual care for patients with moderate or severe upper limb functional limitation. The RATULS trial started in 2014 and was completed at the end of 2018.

Bionik Laboratories’ financial highlights for Q1 of fiscal year 2020 ended June 30, 2019 include Sales increasing to $790,379 for Q1 2020 versus $501,333 for Q1 2019. Margins increased to 57.5 percent in Q1 2020 from 49.5 percent in Q1 2019.

Moreover, highlights for Q1 of fiscal year 2020 ended June 30, 2019 and recent weeks include the Company completing the sale of three InMotion™ Arm therapy robots. This includes the recently released InMotion™ Arm/Hand system to Bionik (China) Medical Technology Co. Ltd. as part of the progressive implementation of its joint venture that it entered into in 2017. Bionik also sold five InMotion™ robots to U.S. customers.

Bionik Laboratories Corp. (BNKL), closed Wednesday's trading session at $3.15, even for the day, on 5 volume. The average volume for the last 3 months is 101 and the stock's 52-week low/high is $1.00/$100.00.

chart

Edgewater Wireless Systems, Inc. (KPIFF)

StockPulse, TalkMarkets, OTC Markets, Stockhouse, Capital Cube, Stockwatch, Insider Tracking, Trading View, GuruFocus, MarketWatch, and Wallet Investor reported previously on Edgewater Wireless Systems, Inc. (KPIFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Edgewater Wireless Systems, Inc. concentrates on Wi-Fi infrastructure with its patented WiFi3™ technology and Next Generation Access Points. The Company commercializes inventive wireless technologies for the service provider market. It is developing substantially improved Wi-Fi network performance across a variety of industries and challenging environments with first-rate performance, high flexibility, and consummate security. Formed in 1988 by Edgewater Computer Systems, Edgewater Wireless Systems is headquartered in Ottawa, Ontario.

Edgewater has a worldwide distribution network. The Company has invested more than $50 Million in the development of Edgewater Wireless Products. It has sales partners in the U.S., the United Kingdom (UK), Brazil, Peru, and Asia.

Edgewater Wireless is patented, standards-compliant Wi-Fi delivering manifold concurrent channels of transmit and receive on a single radio in 2.4GHz & 5GHz – called Wi-Fi Spectrum Slicing. MCSR powers its products. Edgewater Wireless WiFi3™ powered access point products enable unique service providers to plan, build, and deploy reliable, high-capacity services (such as VoWiFI) for high-density & data demand in any environment.

Edgewater delivers the highest channel density available on the contemporary market. The Company utilizes Edgewater Wireless patented technology that enables numerous channels on a single chip. As a result, aggregate output on a single WiFi3™ powered AP will outperform traditional, single channel APs.

Edgewater Wireless Systems, in joint development with CableLabs®, announced earlier this year the availability of Dual Channel Wi-Fi™ in public open source. Developed jointly by CableLabs and Edgewater Wireless Systems, code to support Dual Channel Wi-Fi™ has been released into the OpenWrt repository. CableLabs® is a non-profit innovation and R&D lab. It was founded by members of the cable television industry.

On August 7, 2019, Edgewater Wireless Systems officially unveiled strong new Dual Channel Wi-Fi™ software for the international Linux OpenWrt development community. The work was done in conjunction with CableLabs®’ plan to drive worldwide adoption of Dual Channel Wi-Fi™ for more efficient and reliable connectivity.

Edgewater Wireless Systems have two distinct directions. One is in the Enterprise market, where the Company has validated its innovative technology design with players such as Kroger and Mediacom. The second is the massive Consumer (Home) market where Edgewater has made major progress with its alliance with CableLabs.

Edgewater Wireless Systems, Inc. (KPIFF), closed Wednesday's trading session at $0.0966, off by 3.40%, on 6,605 volume with 4 trades. The average volume for the last 3 months is 35,771 and the stock's 52-week low/high is $0.050999999/$0.120399996.

chart

First Acceptance Corporation (FACO)

Zacks, TipRanks, MacroTends, Research Pool, Investing.com, InvestorsHub, Insider Tracking, GlobeNewswire, Stockopedia, OTC Markets, Simply Wall St, Wallet Investor, Stockwatch, Glassdoor, Digital Journal, and Stockhouse reported beforehand on First Acceptance Corporation (FACO), and we also report on the Company, here at the QualityStocks Daily Newsletter.

First Acceptance Corporation, by way of its subsidiaries, operates as a retailer, servicer, and underwriter of non-standard personal automobile insurance and other ancillary products in the United States. The Company’s insurance operations produce revenue from selling these products in 17 States. At March 31, 2019, First Acceptance leased and operated 348 retail locations and a call center staffed with employee-agents. Established in 1969, First Acceptance has its corporate office in Nashville, Tennessee. The Company’s shares trade on the OTC Markets’ OTCQX.

Currently, First Acceptance conducts its insurance servicing and underwriting operations in 15 States and operates only as an insurance agency in two States. Additionally, it is licensed as an insurance company in 11 States where it does not conduct any business.

Products that First Acceptance offers include Auto Insurance, Motorcycle Insurance, Roadside Assistance, Renters Insurance and Homeowners Insurance. Products offered also include Commercial Insurance, Pet Insurance, Life Insurance, and Travel Insurance.

The Company’s employee-agents chiefly sell non-standard personal automobile insurance products underwritten by First Acceptance and via third-party carriers for which the Company receives a commission. In addition, First Acceptance offers an assortment of additional commissionable products. Furthermore, in most States, its employee-agents sell an insurance product providing personal property and liability coverage for renters that is underwritten by First Acceptance.

Recently, First Acceptance reported its financial results for the three and six months ended June 30, 2019. Income Before Income Taxes, for the three months ended June 30, 2019 was $7.8 million, versus $6.2 million for the three months ended June 30, 2018. Net Income for the three months ended June 30, 2019 was $6.1 million, versus $4.8 million for the three months ended June 30, 2018. Diluted Net Income Per Share was $0.14 for the three months ended June 30, 2019, versus $0.11 for the same period in the previous year.

Income Before Income Taxes, for the six months ended June 30, 2019 was $16.1 million, versus $13.5 million for the six months ended June 30, 2018. Net Income for the six months ended June 30, 2019 was $12.6 million, versus $10.2 million for the six months ended June 30, 2018. Diluted Net Income Per Share was $0.30 for the six months ended June 30, 2019, versus $0.25 for the same period in the previous year.

First Acceptance Corporation (FACO), closed Wednesday's trading session at $0.90, up 8.4337%, on 11,200 volume with 11 trades. The average volume for the last 3 months is 9,187 and the stock's 52-week low/high is $0.700999975/$1.50.

chart

Guard Dog, Inc. (GRDO)

Penny Stock Base, Hot OTC Stocks, OTC PR Wire, TMXmoney, Market Screener, Nasdaq, Stockwatch, Stockopedia, 24hgold, Stockhouse, Otc.watch, News to Watch, TradingView, Morningstar, 4-Traders, and InvestorsHub reported earlier on Guard Dog, Inc. (GRDO), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Guard Dog, Inc. is an opportunity investor looking to finance fresh ideas. Mr. George Sharp, a long-time whistleblower and advocate against microcap fraud, leads the Company. Mr. Sharp is a former consultant to OTC Markets Group, Inc. Currently, Guard Dog is considering investing in an existing project in the social media arena. incorporated in 2005, the Company has its head office in Boulder City, Nevada. Guard Dog’s shares trade on the OTC Markets.

Guard Dog has submitted a Letter of Intent (LOI) to Starsona, Inc., offering to make a multimillion dollar investment into the company. Starsona management signed the LOI. Starsona is an application development company.

Guard Dog and Starsona have agreed to extend the terms of the earlier announced LOI, and specifically, the deadline for the execution of a Definitive Agreement to September 20, 2019. Mr. Sharp stated, “The extension was necessary due to the summer vacation period during which it is difficult to assemble all the necessary parties in order to make the deal work. It is also management’s desire to have the name change and pending reverse split be at or near completion at the time the Definitive Agreement is executed, so that financing timelines can be determined more accurately.”

In late August, Mr. Sharp announced that the Company issued debentures to independent parties in the amount of $150,000, in exchange for cash. Under the terms of the non-brokered, 12 month 15 percent notes, the financiers have the option to convert any part of the principal and interest @ $.0032 per share, on a post-split basis. The funds will be used for administration and operation expenses of Guard Dog. This includes legal, accounting, regulatory and other required expenditures. The funds will also be used for an initial payment towards the ultimate investment in Starsona, once the Definitive Agreement has been executed.

Guard Dog, Inc. (GRDO), closed Wednesday's trading session at $0.0005, even for the day, on 1,250,000 volume with 4 trades. The average volume for the last 3 months is 9,447,281 and the stock's 52-week low/high is $0.0003/$0.005499999.

chart

MRI Interventions, Inc. (MRIC)

EarningsCast, TipRanks, YCharts, Equity Clock, 4-Traders, Last10k, Street Insider, Market Screener, Wallet Investor, Stockhouse, InvestorsHub, Simply Wall St, Trading View, and Proactive Investors reported beforehand on MRI Interventions, Inc. (MRIC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MRI Interventions, Inc. creates inventive platforms for performing the next generation of minimally invasive surgical procedures in the brain. A medical device company, it develops and commercializes unique platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or MRI guidance. The Company is developing products designed for navigation, ablation, deep brain stimulation, biopsy, aspiration and gene therapy. MRI Interventions has its corporate office in Irvine, California.

The Company has two product platforms: the ClearPoint® system and the ClearTrace system. Its ClearPoint® system is in commercial use. It is used to perform minimally invasive surgical procedures in the brain. The ClearTrace system is still in development. It will be used to perform minimally invasive surgical procedures in the heart. Both systems use intra-procedural magnetic resonance imaging to guide the procedures. The design of both systems is to work in a hospital’s existing MRI suite.

MRI Intervention’s belief is that its ClearPoint system may enable physicians to treat patients who otherwise may not be treated using current surgical techniques. Furthermore, by providing direct, intra-procedural visualization, MRI believes its ClearPoint system could lessen the amount of time needed to perform procedures and enable physicians to treat more patients in a given period of time.

MRI Interventions’ Chief Executive Officer, Mr. Joe Burnett, will present at the Sidoti Fall Investor Conference on Wednesday, September 25, 2019. The event will take place at the Grand Hyatt Hotel in New York City. Mr. Burnett will conduct a group presentation at 3:20 p.m. Eastern Time. In addition, he will be available to meet with interested parties throughout the day.

Last month, MRI Interventions announced that its ClearPoint Neuro Navigation System recently completed its 3,000th neurosurgical procedure. Mr. Burnett said, “This milestone is a testament to the value surgeons are placing on precision guided therapy, especially in neurosurgery where the stakes are the highest. Although the timing is coincidental, we were thrilled to share this success with the team at the University of California, San Francisco, who have partnered with us for the last decade in refining our platform and ensuring the voice of not only the doctor, but also that of the patient, is included in every improvement.”

MRI Interventions, Inc. (MRIC), closed Wednesday's trading session at $5.06, up 2.2222%, on 161,169 volume with 895 trades. The average volume for the last 3 months is 23,407 and the stock's 52-week low/high is $1.33000004/$5.50.

chart

Pharming Group N.V. (PHGUF)

NetworkNewsWire, Zacks, TMXmoney, Business Glitz, MacroTrends, GlobeNewswire, Macroaxis, Stockhouse, Market Screener, Market Wire News, Wallet Investor, TradingView, Dividend Investor, and InvestorsHub reported earlier on Pharming Group N.V. (PHGUF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Pharming Group N.V. is a specialty pharmaceutical company headquartered in Leiden, the Netherlands. It is developing unique products for the safe, effective treatment of rare diseases and unmet medical needs. The Company’s lead product is RUCONEST® (conestat alfa). This is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the United States, Israel and South Korea. Pharming Group lists on the OTC Markets.

The Company’s technology platform includes an innovative, GMP-compliant, validated process for the production of pure recombinant human proteins. It has proven capable of producing industrial quantities of high quality recombinant human proteins in a more economical and less immunogenetic way versus present cell-line based methods. Currently, leads for enzyme replacement therapy (ERT) for Pompe and Fabry's diseases are being optimized, with more programs not involving ERT also being presently explored at an early stage.

Pharming has a long-term partnership with the China State Institute of Pharmaceutical Industry (CSIPI), a Sinopharm company, for joint international development of new products, beginning with recombinant human Factor VIII for the treatment of Haemophilia A. Pre-clinical development will take place to international standards at CSIPI and are funded by CSIPI. Manufacturing for the Chinese market and to provide additional supply for Pharming will take place at CSIPI's affiliate, the Chengdu Institute of Biological Products Co. Ltd. Clinical development will be shared between the partners with each partner taking the costs for their territories under the partnership.

Regarding the above-mentioned RUCONEST®, it is is also being examined for approval for the treatment of HAE in young children (2-13 years of age). It is also being evaluated for different additional follow-on indications.

This past July, Pharming Group presented its (unaudited) interim financial report for the first half year ended June 30, 2019. The Company delivered a 31 percent increase in Revenue, a 51 percent increase in Operating Profit, and a 60 percent increase in Net Profit year-on-year. Pharming delivered a 21 percent increase in Revenue, with increases in Operating Profit and Net Profit versus Q1 2019.

Pharming Group N.V. (PHGUF), closed Wednesday's trading session at $1.37, up 12.2951%, on 1,000 volume with 1 trade. The average volume for the last 3 months is 7,197 and the stock's 52-week low/high is $0.744006991/$1.39999997.

chart

Trucept, Inc. (TREP)

Stock News Now, Stockopedia, StockPulse, Infront Analytics, Business Insider, InvestorsHub, Investing Online, PR Newswire, Biz Journals, and Market Screener reported previously on Trucept, Inc. (TREP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Trucept, Inc. is a top consulting and service provider to the Professional Employer Organization and Consumer Goods industries. Through its subsidiaries, the Company provides professional employer organization staffing and business processing services to small and medium-size businesses in the U.S. The Company formerly went by the name Smart-Tek Solutions, Inc. It changed its corporate name to Trucept, Inc. in January of 2013. Trucept is based in San Diego, California.

The Company’s services enable customers to outsource human resources tasks. This includes payroll processing, workers' compensation insurance, health insurance, employee benefits, 401k investment services, personal financial management, and income tax consultation primarily related to staffing comprising staff leasing, temporary staffing, and co-employment. Additionally, Trucept provides healthcare staffing services.

Trucept announced in June 2019 the expansion of its Strategic Marketing and Technology products and services by appointing Mr. Fawad Nisar as Executive Vice President for its new wholly-owned subsidiary, Trucept Marketing, Inc. Mr. Nisar spent 13 years at Trellist Marketing & Technology, providing business consulting, brand and marketing strategy, and technology expertise to Fortune 500 enterprise clients in healthcare, pharmaceuticals, retail, manufacturing, and financial industries. He also brings valuable expertise within the Cannabis industry, especially in product development, sales & marketing of Cannabidiol (CBD). Trucept will assist marketing partners with a CBD line to wholesalers and distributors, with a processing and production capacity of 52kg of pure CBD oil per week.

Last month, Trucept published its Q2 results for 2019. The Company reported a Gross Profit of $1.1 million. This represents an increase of approximately 30 percent. The Company earned a Net Profit of roughly $177,000 for the period ending June 30. This represents an increase of 41 percent from the previous quarter.

Mr. Norman Tipton, Chief Executive Officer of Trucept, said, "Trucept continues to negotiate disputed liabilities and has successfully reduced them by approximately $2.6 million, for a net income increase of about 37 percent from the previous quarter."

Trucept, Inc. (TREP), closed Wednesday's trading session at $0.02576, up 12.00%, on 65,000 volume with 6 trades. The average volume for the last 3 months is 26,871 and the stock's 52-week low/high is $0.0063/$0.195999994.

chart

Scientific Industries, Inc. (SCND)

Zacks, Real Investment Advice, OTC Markets, Whale Wisdom, Capital Cube, Wallmine, Wallet Investor, Simply Wall St, Stockhouse, Stockopedia, Market Screener, Marketbeat, Proactive Investors, and InvestorsHub reported previously on Scientific Industries, Inc. (SCND), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Scientific Industries, Inc. designs, manufactures, and markets an array of laboratory equipment. The Company is the world leader in vortexing technologies. The Vortex-Genie Family is based upon, and originates from, the original Scientific Industries Vortex Jr. Mixer, manufactured before 1962. Scientific Industries provides benchtop laboratory equipment, customized catalyst research instruments, and bioprocessing systems and products globally. The Company is based in Bohemia, New York.

Scientific Industries is best known as the designer and manufacturer of the world-renowned Vortex-Genie® laboratory vortex mixer and shaker. This is part of a complete line of other Genie™ brand lab products. These products include microplate shakers and mixers, cell disruptor and homogenizers, magnetic stirrers, orbital shakers, rotators, rockers, and incubators.

All Genie™ products are made in the United States in its Bohemia headquarters. The Company’s products are typically used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, chemical companies, and medical device manufacturers.

In 2006, Scientific Industries diversified by acquiring Altamira Instruments. Altamira is a manufacturer of custom catalyst characterization instrumentation and bench-scale micro-reactor systems for industrial and research use globally. Moreover, in 2014, Scientific Industries expanded its benchtop laboratory equipment business with the acquisition of the Torbal product line. This is a highly reputable brand with a similar long history of quality and reliability, therefore adding a laboratory scales and pharmacy pill counters product line.

Furthermore, in 2016, Scientific Bioprocessing, Inc. was relaunched. This is a subsidiary of Scientific Industries. Scientific Bioprocessing specializes in non-invasive pH and DO monitoring in cell cultivation via its patch sensor based technology acquired by Scientific Industries in 2011.

For the three and nine months ended March 31, 2019, Scientific Industries reported Net Income of $93,600 ($.06 per basic share) and $354,100 ($.24 per basic share) versus a Net Loss of $37,700 ($.03 loss per basic share) and a Net Loss of $351,500 ($.24 loss per basic share) for the three and nine months ended March 31, 2018, respectively. It reported Revenues of $3,053,500 and $7,255,300 for the three and nine months ended March 31, 2019, versus Revenues of $2,099,300 and $5,272,600, respectively, for the three and nine months ended March 31, 2018.

Scientific Industries, Inc. (SCND), closed Wednesday's trading session at $7.47, up 20.1931%, on 300 volume with 2 trades. The average volume for the last 3 months is 445 and the stock's 52-week low/high is $3.20000004/$7.46999979.

chart

LiCo Energy Metals, Inc. (WCTXF)

Penny Stock Hub, SmallCapVoice, Metals News, Market Screener, Streetwise Reports, OTC Markets, Dividend Investor, Emerging Growth, Stockhouse, InvestorsHub, Barchart, MarketWatch, and Stock of the Week reported previously on LiCo Energy Metals, Inc. (WCTXF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Incorporated in 1998, LiCo Energy Metals, Inc. conducts exploration for metals used in the production of lithium-ion batteries. The Company has four ongoing projects in mining-friendly jurisdictions within the United States, Canada, and Chile. It has a growing portfolio of promising projects, all with goals of developing battery-grade lithium or cobalt.

LiCo Energy Metals is based in Vancouver, British Columbia. The Company lists on the OTC Markets’ OTCQB. The Company previously went by the name Wildcat Exploration Ltd. It changed its name to LiCo Energy Metals, Inc. in October of 2016.

LiCo’s projects include the Glencore Bucke Property, the Teledyne Cobalt Project, the Dixie Valley Lithium Project, and the Black Rock Desert Lithium Project. The Glencore property consists of 16.2 hectares. It sits along the west boundary of the Company’s Teledyne Cobalt Project.

The Teledyne Cobalt Project comprises 5 mining claims and 6 staked crown claims in the Buck and Lorrain Townships, in the district of Temiskaming, Ontario. This project covers 115.5 hectares of mining and surface rights, with an additional 439.1 hectares of staked crown claims.

LiCo Energy Metals previously entered into an option to acquire 100 percent, Net 3 Percent Smelter royalty to acquire 348 claims in the Dixie Valley Exploration Project in Churchill County, Nevada. Moreover, it entered into an option agreement where it may earn an undivided 100 percent interest subject to a 3 percent Net Smelter Return Royalty in the existing Black Rock Desert Lithium Project. This Project consists of 199 placer claims (3,980 acres/1,610 hectares) in southwest Black Rock Desert, Washoe County, Nevada.

LiCo Energy Metals entered into an Option Agreement with Surge Exploration, Inc. Surge can earn an undivided 60 percent interest in the Glencore Bucke and the Teledyne Cobalt Properties in Cobalt Ontario, subject to certain cash, share and exploration payments to LiCo. Upon Surge having exercised the Option, Surge Exploration will have earned an undivided 60 percent interest in the Cobalt Properties. Also, the parties will enter into a Commercially Reasonable and Definitive Joint Venture Agreement.

Recently, LiCo Energy Metals provided interim assay results from drill holes GB18-22 to GB18-30, drilled on its Glencore Bucke Cobalt Property (Cobalt, Ontario). During the late fall of 2018, LiCo completed 4,272 m/14,016 ft. of diamond drilling in 33 holes on the Glencore-Bucke and Teledyne Cobalt Properties: 2,559 m/8,396 ft. were completed in 24 drill holes on the Glencore Bucke Property, and 1,713 m/5,620 ft. in 9 drill holes on the Teledyne Cobalt Property.

On the Glencore-Bucke Property, drill holes GB18-22 to GB18-30 tested the Northwest and Main Zones with the aim of intersecting mineralized zones along strike and vertically above and below prior intersections reported in LiCo’s 2017 drilling program on the same properties. Highlights from diamond drill holes GB18-22 to GB18-30 include GB18-26 0.29 % Co over 0.25 m from 79.25 to 79.50 m; and GB18-27 0.47 % Co, 33.1 ppm Ag, 0.82% Cu over 2.33 m from 94.42 to 96.75 m, including 1.3% Co, 65.8 ppm Ag, 0.97% Cu over 0.83 m from 94.42 to 95.25 m.

Highlights also include GB18-29 1.28% Cu over 3.75 m from 61.75 to 65.50 m, including 0.24% Co, 0.43% Cu from 63.00 to 63.40 m, and GB18-30 0.70 % Co over 0.50 m from 40.00 to 40.50 m. In addition, there were no significant results for drill hole GB18-22.

LiCo Energy Metals, Inc. (WCTXF), closed Wednesday's trading session at $0.0312, up 26.8293%, on 550 volume with 3 trades. The average volume for the last 3 months is 17,554 and the stock's 52-week low/high is $0.017/$0.180299997.

chart

Alltemp, Inc. (LTMP)

MissionIR, Stock Communications Group, Dividend Investor, 4-Traders, InvestorsHub, GuruFocus, The Street, Investors Hangout, Barchart, StockInvest, MarketWatch, Stockhouse, Morningstar, Wallet Investor, Market Screener, and Capital Cube reported earlier on Alltemp, Inc. (LTMP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Alltemp, Inc. is a developer of proprietary, environmentally-friendly, refrigerant technologies. The Company has developed a proprietary refrigerant technology, called alltemp®. This is a proven replacement for many global refrigerants that have adversely affected the worldwide environment.  Alltemp is based in Westlake Village, California.

alltemp®’s refrigerants are for the commercial and residential markets. alltemp® is the Company’s solution for the replacement of R-407c, R-134a, R-404a, and HCFC-22, known as R-22, but which is quickly being phased out in all developed nations because of environmental concerns over its strong effect on the depletion of the Earth's ozone layer.  

alltemp® refrigerants have broad applications. These range from Heating Ventilation and Air Conditioning (HVAC), to refrigeration and foam insulation, to industrial solvents. alltemp® solutions provide a sustainable, eco-friendly, true drop-in refrigerant. It meets the Montreal/Kyoto Protocols and EPA  (Environmental Protection Agency) standards with the lowest Global Warming Potential for any non-flammable HFC. alltemp®  yields a 27 percent average decrease in kWh,  without loss in capacity.

Alltemp successfully completed two years of early adopter testing of its alltemp® refrigerant at several Fortune 100 companies' facilities for its Montreal and Kyoto Protocol compliant refrigerant. Furthermore, test results revealed that alltemp® yielded significant average savings in energy consumption. This is while maintaining capacity.

Alltemp announced in January 2018 that it released a new refrigerant alternative for R-404A applications called alltemp® 4. This is a drop-in refrigerant. R-404A has one of the highest GWPs (Global Warming Potential) of any HFC refrigerants. It is quickly being phased out in the European Union (EU) and other developed countries.

Alltemp announced in March 2018 that flashpoint chamber testing conducted by DEKRA Insight confirmed that alltemp® refrigerant has zero flammability. A minimum of 20 different chamber tests in the liquid phase and 20 vapor phase tests, with temperatures as high as 60º C = 140º F, revealed zero flammability and no ignition with alltemp® refrigerant.

Alltemp has its R-410A replacement refrigerant, designated alltemp® H. Like the Company’s other refrigerants, alltemp® H is engineered to use the same anti-corrosive and non-flammable alltemp® core technology that provides major energy efficiencies and meets ASHRAE A1 safety classification standards.

R-410A was designed to replace R-22, which has a substantial environmental impact and Ozone Depletion Potential (ODP). The lower the GWP value, the better the refrigerant is for the environment. R-410A has a Global Warming Potential (GWP) rating of 2,088. Its predecessor R-22 has a GWP rating of 1700.

Alltemp, Inc. (LTMP), closed Wednesday's trading session at $0.0386, up 13.1965%, on 50,500 volume with 9 trades. The average volume for the last 3 months is 78,107 and the stock's 52-week low/high is $0.029999999/$0.148000001.

chart

ProBility Media Corporation (PBYA)

NetworkNewsWire, MarketWatch, Morningstar, Marketwired, Barchart, The Street, OTC Markets, Dividend Investor, InvestorsHub, StockTrot, Topstocksnews, Marketbeat, Penny Stock Hub, Wallmine, YCharts, Simply Wall St, and Stocks to Buy Now reported previously on ProBility Media Corporation (PBYA), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

ProBility Media Corporation is a technology business offering immersive technologies, digital learning and compliance solutions for the education and training markets. The Company serves customers from the individual to the small business to the enterprise level corporation. In January 2018, ProBility Media acquired DISCO Learning Media, an online course developer and digital publisher.

ProBility Media has its head office in Houston, Texas, with offices in Florida, New York, and Vermont. ProBility Media is an education technology (EdTech) company. The Company’s shares trade on the OTC Markets. The Company offers premier training courses and materials and works to prepare the workforce for excellence. It is executing the strategy of defragmenting the marketplace of thousands of disparate companies through acquiring smaller companies in the areas of its expertise and organically building revenue through synergies.

ProBility Media is looking for acquisition targets that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, and qc firms and additional vocational industries. ProBility, by way of its electrical training division, is becoming the largest wholesaler of electrical codes and exam prep material in the United States. In addition, through its construction training division, it offers programs in 22 states. This division serves one of the largest certification markets in the United States.

The Company’s DISCO Learning Media entered into an agreement to help The University of Texas System launch Careers in Chemistry, a new game-based experience inside Minecraft: Education Edition aimed at highlighting chemistry-related career opportunities to high school students. University of Texas at Austin associate professor of instruction in chemistry and science entertainer Dr. Kate Biberdorf will help guide the project and supervise the career curriculum.

Austin-headquartered education agency, DISCO Learning Media, provided instructional and media content support. DISCO Learning Media, a creative education agency, eCourse developer and digital publisher, is a division of Probility Media.

ProBility Media Corporation (PBYA), closed Wednesday's trading session at $0.0001, up 9,900.00%, on 100,000 volume with 1 trade. The average volume for the last 3 months is 1,977,647 and the stock's 52-week low/high is $0.000000999/$0.026499999.

chart

Blox, Inc. (BLXX)

Stockwatch, OTC Markets Group, Insider Wisdom, SmallCapVoice, Dividend Investor, PennyStocks24, Capital Cube, Investors Hangout, Marketwired, Savvy Trader Resource, and Real Investment Advice reported previously on Blox, Inc. (BLXX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Blox, Inc.’s vision is to pioneer the development of mining projects through applying green innovation to traditional mining methods and combining renewable energy and technology into the process. The Company’s plan is to become a global leader in the production of “green minerals”. Blox Minerals is a wholly-owned subsidiary of Blox, Inc. Blox is headquartered in Vancouver, British Columbia and the Company lists on the OTC Markets’ OTCQB.

Blox defines “green minerals” as minerals produced using technologies, best practices, and mine processes implemented to lessen the environmental impacts associated with the extraction and processing of metals and minerals. The Company’s plan is to use renewable energy and technology in the production of green minerals with the aim of turning expensive costs into profits through utilizing renewable energy plants to power its varied projects.

A vital aspect of Blox’s mandate is to implement clean energy into the mining process. This is to effectively “green” the mining process and minimize its environmental impact through lower hydrocarbon emissions. Blox’s plan is to build a portfolio of gold and other minerals and produce them in a socially and environmentally friendly way. Its key concession holdings are in Ghana and Guinea, West Africa. Its projects include Pramkese, Osenase, Asamankese, and Mansounia.

The Mansounia Exploration Licence is centered on Latitude 10º 23’ N and Longitude 9º 47’ W in the Kouroussa Prefecture, Kankan Region, in Guinea, West Africa. It encompasses a surface area of 145 square kms. At Mansounia, significantly fresh rock mineralization has been intersected and as of July 2016, remains unexplored. Mansounia is a priority development asset for the Company.

Blox has entered into a Strategic Alliance Agreement with Ashanti Sankofa, Inc. With this Strategic Alliance Agreement, both parties agreed to grant to the other party a right of first refusal to enter into a joint venture (JV) on any of their respective properties and/or projects and that any future acquisition of natural resource properties, which may be acquired by either party that contains, but is not limited to, gold, precious metals, technology metals or diamonds (Natural Resource Properties), the acquiring party will grant to the other party a right of first refusal to participate in a JV on such Natural Resource Property that shall be at the sole discretion of the acquiring party.

Recently, Blox announced that results received from its auger drilling campaign at Mansounia identified five additional targets. This includes doubling the strike of the Mansounia South Prospect to more than 5 km long. Mansounia contains a current JORC Compliant resource of 1.29-million ounces at a pre-feasibility stage. The project is in the highly prospective Siguiri Basin region of Eastern Guinea.

Mr. Trevor Pickett, Chief Executive Officer of Blox, said last month, "I am excited about the new drill targets identified and the extensions of the drill ready targets unveiled by the auger drilling. Anomalies were revealed in every drill line commenced, which is a very positive sign. These results have given us confidence to move forward with our plans to raise capital to complete the current auger program and then plan high quality resource extensional drilling. We are also well advanced towards the submission of our Mining License application for the Mansounia Gold Project."

Blox, Inc. (BLXX), closed Wednesday's trading session at $0.20, up 63.9344%, on 1,000 volume with 1 trade. The average volume for the last 3 months is 1,859 and the stock's 52-week low/high is $0.026/$0.25.

chart

Miramont Resources Corp. (MRRMF)

Stockhouse, Stockwatch, Wallet Investor, InvestorX, Global Mining Review, Junior Mining Network, MarketWatch, Dividend Investor, Canadian Mining Report, OTC Markets, Pinnacle Digest, Wallmine and 4-Traders reported on Miramont Resources Corp. (MRRMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Miramont Resources Corp. engages in the exploration and development of its Peruvian projects. Its emphasis is on acquiring and developing mineral prospects within world-class belts of South America. The Company was previously known as Miramont Capital Corp. It changed its name to Miramont Resources Corp. in November of 2016. Miramont Resources has its corporate office in Vancouver, British Columbia.

The Company entered into a share exchange agreement in June of 2017 to acquire 100 percent of Puno Gold Corp., a privately held Ontario corporation, and Minera Puno Gold SAC, a Peruvian subsidiary of Puno Gold. Minera Puno engages in mineral exploration and development in Peru. It holds options to acquire 100 percent interest in the 988.69-hectare Cerro Hermoso project and the 4,400-hectare Lukkacha project (both in southern Peru).

Cerro Hermoso is in the Puno region, 60 kilometers west of the city of Juliaca, and 5kms west of the supply town of Santa Lucia. Cerro Hermoso is a breccia-pipe prospect targeting Au, Ag, Cu, Zn and Pb mineralization.

Lukkacha is in the Tacna region. It is 55 kilometers east-southeast of the operating Toquepala mine of Southern Peru Copper. The project (a porphyry copper prospect) is 60 kilometers north of the city of Tacna and 8 kilometers from the supply town of Tarata.

Recently, Miramont Resources announced that it entered into an option agreement to acquire the rights to the Milenos 32 concession contiguous to its Cerro Hermoso project. The concession gives the Company complete control of the Pocomoro zone. This is where highly anomalous copper and silver has been identified in surface rock samples. The combined area of the project is currently 1318 hectares. It includes the whole diatreme system, which controls mineralization in the district.

Miramont Resources also recently announced that the Peruvian Ministry of Energy and Mines (MEM) determined that Miramont is not eligible for an automatic approval of its drilling permit as it is possible that exploration drilling may affect indigenous communities. The Company stated that it appreciates more review to ensure that any potentially affected communities are identified and fully consulted. As Miramont Resources’ Environmental Impact Statement has already been approved, this is the final level of review required before issuance of drilling permits.

Miramont Resources Corp. (MRRMF), closed Wednesday's trading session at $0.1106, up 29.3567%, on 90,800 volume with 7 trades. The average volume for the last 3 months is 48,780 and the stock's 52-week low/high is $0.071000002/$0.483999997.

chart

Continental Energy Corp. (CPPXF)

TopPennyStockMovers, Streetwise Reports, and Agoracom reported previously on Continental Energy Corp. (CPPXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Continental Energy Corp. is an emerging developer of conventional and alternative energy capacity integrated with upstream and downstream petroleum supply within the Republic of Indonesia. Listed on the OTC Markets, the Company’s commitment is to developing hybrid renewable electrical power generation capacity and profitably operating mini-grid distribution networks in the huge, under-served markets of the fast-growing economies encircling the Indian Ocean Rim.

Established in 1984, Continental Energy is headquartered in Vancouver, British Columbia. The Company previously went by the name Continental Copper Corp. It changed its corporate name to Continental Energy Corp. in October of 1997.

The Company’s core competency exists in Indonesia. It has 30 years of experience in Indonesia. This has given Continental Energy the business relationships and local operating experience necessary to capitalize on the rising energy demand in this country.

In addition, Continental Energy has its business combination with the Ruaha River Power Company. This business combination provided instant entry into Tanzania. This is where the best-in-Africa commercial incentives for small scale renewable energy developers are in place to foster new supply of power to off-grid communities.

Recently, Continental Energy announced the filing on SEDAR of its audited consolidated financial statements and its management discussion and analysis for its Fiscal 2017 year ended June 30, 2017. Continental had a Loss from Operations of $439,606 during Fiscal 2017 versus a Loss from Operations of $473,289 during Fiscal 2016. This represents a decrease of $33,683, mainly because of lower professional fees and share-based payments.

The Company had a loss per share of $0.00 in both 2017 and 2016. Continental’s administrative costs were lower by $14,428 in 2017 versus 2016. This was chiefly because of reduced professional fees: 2017 - $376,842; and 2016 - $391,270. As at the end of this Fiscal Year 2017, Continental Energy’s Working Capital deficit was $1,721,256 versus a Working Capital deficit of $1,282,380 at the end of Fiscal 2016.

Continental Energy Corp. (CPPXF), closed Wednesday's trading session at $0.026, up 30.00%, on 4,000 volume with 1 trade. The average volume for the last 3 months is 17,596 and the stock's 52-week low/high is $0.008/$0.048999998.

chart

The QualityStocks Company Corner

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

The Stock Day Podcast recently welcomed Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (OTCQB: PBIO) ("the Company"), to discuss PBIO on Stock Day with its host Mr. Everett Jolley. PBIO is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Wednesday's trading session at $3.08, up 0.325733%, on 22,611 volume with 65 trades. The average volume for the last 3 months is 11,706 and the stock's 52-week low/high is $1.25/$4.0999999.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will present, via webcast, at the Singular Research Midwestern Values Conference on September 19, 2019. Genprex Chairman and CEO Rodney Varner will lead the company's webcast presentation. The presentation is scheduled to begin at 4:00 PM Central Time, and interested parties may register for the webcast via the Singular Research website. To view the full press release, visit: http://nnw.fm/IxlP7.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Wednesday's trading session at $0.9227, up 2.5222%, on 29,188 volume with 170 trades. The average volume for the last 3 months is 51,796 and the stock's 52-week low/high is $0.640999972/$2.50.

Recent News

chart

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences Inc. (CSE: WLLW) was featured today in the 420 with CNW by CannabisNewsWire. Reports about illnesses and some fatalities possibly linked to the use of tainted vape cartridges has prompted lawmakers and state officials across the country to look for ways to address this challenge. Massachusetts is one of the states that has come out swiftly to confront this problem head-on.

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Wednesday's trading session at $0.74, up 10.45%, on 223,585 volume with 96 trades. The average volume for the last 3 months is 79,331 and the stock's 52-week low/high is $0.529999971/$5.25.

Recent News

chart

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology Inc. (NASDAQ: POAI) is harnessing its unique, proprietary database of cancer cases using the proven power of artificial intelligence (AI) to revolutionize treatment outcomes for cancer patients. The company works alongside pharmaceutical, diagnostic and biotechnology industry players to develop highly customizable assessment methods that can be applied to both individualize current therapies and develop the next generation of precision therapies, leading to better outcomes for patients.

Predictive Oncology (POAI) is a data and artificial intelligence-driven discovery services company that provides predictive models of tumor drug response to improve patient outcome. Predictive Oncology harnesses the power of artificial intelligence, collaborating with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for patients, which can lead to much more effective treatments.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable development of patient specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Predictive Oncology (POAI), closed Wednesday's trading session at $0.5338, up 0.812087%, on 38,013 volume with 204 trades. The average volume for the last 3 months is 65,221 and the stock's 52-week low/high is $0.419999986/$0.850000023.

Recent News

chart

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions Inc. (OTCQB: SGSI) provides excellent solutions for next-generation wireless networks through its professional services and installation capabilities for service providers and corporate enterprise markets. Part of the mission of Spectrum Global Solutions is to be the premier world-class industry leader providing the best services possible at the highest levels of quality, reliability and safety. Reliability is critical for network performance, and high-quality installations help ensure that the standard is met.

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed Wednesday's trading session at $0.03479, up 5.4242%, on 38,670 volume with 12 trades. The average volume for the last 3 months is 185,579 and the stock's 52-week low/high is $0.014999999/$1.49.

Recent News

chart

HTC Extraction Systems (TSX.V: HTC)

The QualityStocks Daily Newsletter would like to spotlight HTC Extraction Systems (TSX.V: HTC).

HTC Extraction Systems (TSX.V: HTC), a gas, liquids and biomass extractor and refiner, recently entered into a tolling agreement to process five million kilograms of hemp biomass. An article discussing the company reads, “HTC recently announced its entry into a hemp-biomass tolling agreement, which will involve the processing of hemp biomass for the 2019 crop year (http://nnw.fm/FE4Rs). To view the full article, visit: http://nnw.fm/V72pk.

HTC Extraction Systems (TSX.V: HTC) has developed and optimized proprietary technologies designed for biomass extraction, distillation and purification of ethanol and ethanol-based solvents used for the hemp biomass and cannabidiol (“CBD”) industry, as well as gas and liquid extraction. HTC’s extraction & purification systems are engineered to large-scale to reduce capital and operating costs while delivering superior performance measured by reduced energy usage, lowered emissions and improved quality of the product produced.

Advanced Extraction Technologies

For more than 14 years, HTC has developed and optimized proprietary technology and purification systems used for biomass, gas and liquid extraction. These technologies include:

  • LCDesign® – Low-cost design for modular gas, liquid and biomass extraction systems optimizes plant design, thus reducing capital and operating costs.
  • PDOEngine™ – Software-based design algorithms accurately model and simulate gas, liquid and biomass extraction processing.
  • Delta Solvents™ – Custom-designed, ethanol-based solvent mixtures and additives that optimize production and reduce costs. Technology development is being conducted at HTC’s sponsored research facilities at the University of Calgary.

Delta Purification® Technology

HTC’s patented Delta Purification® technology will purify, recycle and reuse the extraction ethanol used in the CBD extraction process while managing and reducing any CBD waste losses through the re-extraction of all wastes collected from the purified ethanol. Current and new technologies include:

  • Delta CBD Reclaiming System: Reclaiming and purifying ethanol for use in CBD extraction from biomass. Reduces required heat to prevent damage of the chemical attributes of the CBD molecule, allowing extracted CBD to meet food-grade targets for human consumption.
  • Delta Solvent Reclaiming System: Reclaiming and purifying ethanol-based solvents, such as single, mixed and formulated amines, for use in natural gas processing and post-combustion CO2 capturing processes.
  • Delta Glycol Reclaiming System: Reclaiming and purifying glycols, such as mono-ethylene glycol and tri-ethylene glycol for use in natural gas dehydration processes.

Hemp Biomass and Tolling Contracts

HTC has entered into a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass from a hemp grower in Saskatchewan, Canada. The hemp grower utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process and extract CBD FSO distillate from the hemp biomass. As a tolling fee payment, HTC will receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services.

Additional hemp biomass tolling contracts with producers and hemp biomass providers are being negotiated in the U.S. for the 2020 hemp crop growing year. HTC will provide “local-to-grower” drying-to-biomass storage capability and transportation of dried biomass to an HTC, location to be determined, future US based, extraction facility. HTC is also in negotiation with a 60,000-acre, recognized Canadian farm leader, who is a significant hemp biomass producer, for a similar hemp biomass tolling contract.

re3™ Technology

Large users of ethanol and solvents for plant oil extraction demand reduced capital and operating costs. HTC’s re3™ (reclaim, recycle, reuse) technology can save up to 30% of the required fluid costs. The increasing cost of new extraction ethanol, combined with the cost of used ethanol disposal, creates a unique opportunity whereby the re3™ technology will create cost savings, while meeting environmental responsibilities.

The growth of ethanol and CO2 used in CBD production has created a new demand for reliable commercial scale ethanol reclaimer systems. The Delta Purification® ethanol system meets this new demand.

Sales and Offtake Agreements

HTC intends to leverage its relationship with its related entity, Purely Canada Foods™, to provide sales and distribution for its Ingredient CBD market under the brand of Purely Canada Hemp™, Purely Canada CBD™, Purely Canada Cannabinoids™. Purely Canada Hemp™ will develop risk managed multi-year ingredient supply contracts with its existing and new Global Food, Beverage and Animal Food Industry Customers.

Project Construction

HTC has focused the Canadian implementation of its BOOM (build, own, operate and maintain) extraction tolling strategy on a location near Regina, Saskatchewan. HTC is currently constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility on six acres of land that will include biomass processing, extraction, implementation of DeltaSolv™ technologies and Delta Purification® systems, distillate and refining equipment, laboratory quality control and testing operations, and on-site office and admin facilities.

Leadership

Chairman, CEO and Director Lionel Kambeitz is a recognized professional in business development and international business relations. He has played a founding role in many other Canadian and U.S.-based companies. Kambeitz has executive experience in a variety of industries including energy, agriculture, food production engineering, and manufacturing.

Jeff Allison, Senior Vice President, Chief Financial Officer and Director, has over 20 years of experience in corporate finance and business development. Prior to joining HTC in 2005, Allison as Vice President assisted with the founding and setup of CUCORP Financial Services in Saskatchewan.

HTC Extraction Systems (TSX.V: HTC), closed Wednesday's trading session at $0.75, even for the day, on 21,450 volume. The average volume for the last 3 months is 209,031 and the stock's 52-week low/high is $0.0800/$1.2400.

Recent News

chart

Geyser Brands Inc. (TSX.V: GYSR)

The QualityStocks Daily Newsletter would like to spotlight Geyser Brands Inc. (TSX.V: GYSR).

Global science-led consumer health care company Geyser Brands Inc. (TSX.V: GYSR) recently announced that it was ready to move forward with a major strategic acquisition following its conditional approval by the TSX Venture Exchange. In a press release issued on August 6, 2019, the company said that it expects to complete the acquisition of Solace Management Group Inc. by the end of the month, subject to the terms of the definitive agreement (http://nnw.fm/8iRHI).

Geyser Brands Inc. (TSX.V: GYSR) is a consumer healthcare company that builds and markets some of the world's most loved cannabis products and brands in the nutraceutical, cosmetics, food and beverage and pet sectors. Using its proprietary nanotechnology formulation, the company delivers creams, beverages, baked goods and tincture formulations with superior bioavailability and water solubility.

NanoFusion Technology

The efficacy of most hemp?products is restricted as the insoluble nature of the molecules prevents most of the product from permeating the skin or entering the body system. Geyser Brands solves this insolubility problem with an advanced delivery system that quickly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency.

Made with all-natural materials, NanoFusion technology offers an array of advantages: enhances penetration for deeper skin penetration; improves the transport of active ingredients for site-specific targeting; delivers active ingredients across cell membranes for release within the cell; provides longer shelf-life and stability of molecules.

Operations

Geyser Brands operates a 7,000-square-foot facility in Port Coquitlam, British Columbia, where its initial cannabis cultivation generated the first revenues out of the company's cultivation license granted in October 2018. Geyser Brands is approved as a licensed producer in compliance with Health Canada standards, which allows the company to pursue its processing and sales license. Obtaining this license will enable the company to extend its products and brands into the regulated Canadian cannabis market and directly to the consumer medical market.

Geyser Brands's integrated production chain and formulation lab develops innovative products using high-quality hemp and CBD for healthy lifestyle brands while its R&D lab produces product formulations designed to enhance bio-availability of hemp and CBD and shelf stability while maintaining all-natural ingredients and ensuring premium quality.

Geyser Brands will continue to seek opportunities to invest into the research and development of unique high-quality proprietary strains and technologies that target specific health-related conditions such as pain and inflammation reduction, insomnia, digestive issues and other commonly known ailments.

Growing Portfolio

Among the brand formulations in Geyser Brand's portfolio are:

  • Apothecary all-natural Hemp Terpene Pain Cream with optimal skin permeation
  • Prohibition Cold Brew Mocha designed with water soluble hemp molecules
  • Apothecary health products created to deliver fast-acting and high bioavailability in a spray formulation
  • Baked hemp infused pet products, designed to alleviate anxiety and pain, created with NanoFusion for dosage control

Management Team

Since 2014, Geyser Brands' CEO and Co-Founder Andreas Thatcher has been a principal at Rhizome Group, an entertainment company focused on building media IP through creative and market development. He previously was a founding partner at Rhizome Capital LLC, a U.S.-based media?investment?company specializing in marketing and distribution financing, and worked in the Investment Banking industry in?London and Toronto. Thatcher holds a master's degree in economics.

CFO Barry McKnight obtained his bachelor's degree from the University of British Columbia and is a Chartered Professional Accountant and?Certified Management Accountant registered in British Columbia. McKnight has over 20 years of experience as the principal of Barry D. McKnight Inc. He formerly was also a director of Indigo Sky Capital Corp. and has been the CFO and a director of the Company since 2016 and Corporate?Secretary of the Company since 2017.

Geyser Brands's Co-Founder Brad Kersch brings a strong business background with over 20 years of experience in?successful startups and working?with Fortune 500 companies. He spent his early years in the advertising and?marketing field and went on to form Hyperware, a clothing?company that sold branded clothing to retailers across Canada?before selling to clothing giant Ocean Pacific (OP). Kersch?became the president of Shoreline Studios, Canada's largest and?oldest?studio for film and TV. In 2014 he started Solace Management Group, a hemp product company focused on pet, cosmeceutical, and nutraceutical markets. As of February 2019, Geyser Brands signed a non-binding LOI to acquire Solace Management. Upon completing the proposed Solace acquisition, Geyser Brands intends to launch into the execution phase of its plan — to take its brands global through retail and digital direct-to-consumer experiences, launching its hemp-infused cannabis brands and products in the U.S., European Union, and Asia, and its CBD-infused line of products in jurisdictions where the therapeutic ingredient is legal.

Kuldip Gill, head of Geyser Brands' R&D program, has more than 35 years of experience in the cannabis industry. Gill built the largest manufacturing facility?in the lower mainland in Surrey, British Columbia, complete with R&D, analytical and quality control labs approved by both the FDA and Health Canada. He has to date created over 3,500 formulas, most notably Lakota pain relief gel. Gill's experience and proven track record is evident in the strongly marketable formulations he has developed and sold worldwide.

Geyser Brands Inc. (TSX.V: GYSR), closed Wednesday's trading session at $0.41, even for the day, on 17,500 volume. The average volume for the last 3 months is 2,519 and the stock's 52-week low/high is $0.409999996/$0.850000023.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) was featured today in the 420 with CNW by CannabisNewsWire. Reports about illnesses and some fatalities possibly linked to the use of tainted vape cartridges has prompted lawmakers and state officials across the country to look for ways to address this challenge. Massachusetts is one of the states that has come out swiftly to confront this problem head-on.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed Wednesday's trading session at $0.3528, even for the day, on 10,134 volume. The average volume for the last 3 months is 13,720 and the stock's 52-week low/high is $0.250999987/$1.12999999.

Recent News

chart

Neutra Corp. (OTCQB: NTRR)

The QualityStocks Daily Newsletter would like to spotlight Neutra Corp. (NTRR).

On September 10, 2019, Neutra Corp. (OTCQB: NTRR) completed a previously announced acquisition of VIVIS Corp., an emerging retail brand of hemp-based wellness and health products, founded to offer clients high quality, potent hemp-extracted solutions. This area of specialization makes VIVIS a great match to the Neutra philosophy, as the company said in a news release (http://nnw.fm/mIF9z).

Neutra Corp. (OTCQB: NTRR) is an early-stage research and development company bringing modern healthy living solutions to a multi-billion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture – one where consumers are demanding access to products that promote health and stave off potential health dangers.

Neutra is concentrating on developing into a vertically integrated company able to cultivate, manufacture and distribute hemp-based cannabidiol (CBD) products. Hemp-based CBD consumer products generated sales of up to $390 million in 2018 with projections pointing to a $3 billion market by 2022, according to the Hemp Business Journal.

Neutra’s new broadened scope, which includes the commercialization of newer, more effective products, aims to capitalize on this worldwide boom. Our company is seeking new and exciting opportunities that can accelerate Neutra’s mission to bring these products to a wider demographic. Our work reflects a renewed dedication to supporting a better body, environment and life for people around the globe.

Acquisitions

  • Vivis – Neutra is expanding its market presence in the rapidly growing hemp-derived CBD market with a letter of intent to acquire Vivis, an emerging retail brand of hemp-based health and nutritional products. Vivis’ hemp-derived CBD products are third-party certified as contaminant-free and of consistent quality and potency. Consumers are increasingly looking for this certification when they buy hemp-based CBD products. With Vivis as the new retail face of Neutra, the company is expecting greater interest in its expanding portfolio of branded products moving to market.
  • J3 Holdings – The signing of a letter of intent to acquire J3 Holdings includes the company’s land and warehouse, as well as a license to cultivate hemp and refine it into usable forms. Neutra has concentrated its early efforts developing business networks and on developing hemp-based CBD products, including supplements and creams. The latest move will enable the company to grow its own hemp supply, giving it more control over the quality of its ingredients.

Partners

  • Surface to Air Solutions is the North American distributor of a patent-pending, water-based solution known as Purteq, a green technology that works similar to photosynthesis.
  • ZeroBlast uses a durable, non-toxic, anti-microbial solution to eliminate all contaminates and kill germs on contact for a period of up to 90 days.

Leadership

Neutra president and CEO Sydney Jim provides strong executive leadership, a network of business contacts and experience implementing solid corporate strategy. Jim has a proven track record of adding value for public company shareholders. He founded Global Visionary Investments where operational support is provided to seven different companies and their subsidiaries. Jim was also the CEO of First Titan Energy, a microcap public company where he was responsible for restructuring the corporate structure, deal sourcing, and leading the company in mergers and acquisitions.

Dr. Scott Cherry is the company’s sports performance medical advisor. He is an energetic physician executive with a passionate focus on health, performance and prevention. Dr. Cherry received emergency medical technician training in the U.S. Navy, a bachelor’s degree in chemistry from Florida State University, medical degree from Nova Southeastern University, and a master’s degree of public health from Uniformed Services University F. Edward Herbert School of Medicine. Dr. Cherry has honed his skills in a variety of medical and executive positions spanning the U.S. Army and Navy, several Fortune 500 corporations, and major health care facilities over the past 20 years.

Neutra Corp. (OTCQB: NTRR), closed Wednesday's trading session at $0.0018, even for the day, on 14,271,705 volume with 52 trades. The average volume for the last 3 months is 22,918,194 and the stock's 52-week low/high is $0.0012/$0.097350001.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) on Tuesday announced the release of its financial and operating results for the fourth quarter and fiscal year ended June 30, 2019. Among the results, the company reported achievement of its first positive Adjusted EBITDA quarter of $3.2 million, a 90% increase in net revenue to $19 million in Q4 2019, up from $10 million in Q3 2019, as well as a 370% increase in fiscal total revenue to $41.8 million in 2019, up from $8.9 million in 2018. To view the full press release, visit: http://nnw.fm/H0k3I.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Wednesday's trading session at $1.064, off by 2.1249%, on 606,859 volume with 605 trades. The average volume for the last 3 months is 393,520 and the stock's 52-week low/high is $0.850000023/$2.03999996.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics (OTCQB: ENDV) develops, manufactures and distributes innovative medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. To view the full article, visit: http://nnw.fm/Y8DOu.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed Wednesday's trading session at $0.0073, off by 8.75%, on 8,342,591 volume with 76 trades. The average volume for the last 3 months is 6,524,621 and the stock's 52-week low/high is $0.0073/$0.066100001.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a leading cannabis branded products company in California, this morning announced the completion of the debt transaction previously announced by Plus on September 11 concerning the issuance of units consisting of subordinate voting shares and warrants in exchange for the settlement of certain debt. To view the full press release, visit: http://nnw.fm/PkB3X.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Wednesday's trading session at $3.64, off by 7.8493%, on 66,681 volume with 169 trades. The average volume for the last 3 months is 38,432 and the stock's 52-week low/high is $2.51999998/$6.00810003.

Recent News

chart

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF)

The QualityStocks Daily Newsletter would like to spotlight IONIC Brands Corp. (OTC: IONKF).

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) is pleased to announce that it has secured eligibility by The Depository Trust Company (DTC) for its shares on the OTC Market in the United States.

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) is a national cannabis holding company building a multistate portfolio of award-winning premium and luxury brands in the cannabis space. Established in 2015, IONIC Brands has demonstrated its ability to expand and operate multiple cannabis concentrate consumer brands in leading markets across the western United States, with current operations in Washington, Oregon, California and Nevada. The company continues to strategically expand nationwide to remain a leader of the highest-value segments in the cannabis market.

With a focus on quality, responsibility and respectability, IONIC’s product lines are pioneering the changing landscape of cannabis consumption. The company’s refinement practices are a result of a passionate commitment to craft the finest, small-batch cannabis oils and cannabis concentrates in the world – without glycols, glycerins or additives.

IONIC’s Certified Clean program verifies that every product leaving the company’s facilities meets or exceeds state mandates on pesticide testing. The testing is conducted by individually testing every batch which ensures and enhances trust and transparency. IONIC recently paired its Certified Clean program with Lucid Green Inc. and its revolutionary technology platform designed to provide vital safety information. Lucid Green’s technology provides a direct-to-consumer data platform, providing instant access to a library of product specific insights by simply scanning the package’s QR code with a smartphone camera.

Elite Brand Portfolio/Acquisitions

  • IONIC, the company’s flagship recreational branded product, is a stylish and sophisticated premium vape pen line that has earned customer loyalty and a reputation as a consistent Top 10 vape brand in Washington state. IONIC’s immediate product line expansion plans include THC/CBD mixes, low-dose products, high-end edibles, CASK oil and device innovation.
  • WW Agriculture cultivates cannabis outdoors on a 140-acre eastern Washington State farm capable of producing up to 100,000 pounds of cannabis for less than $0.10/gram.
  • ZOOTS, a Washington-based edibles company, utilizes patent-protected ultra-clean CO2 extraction hardware to create proprietary formulations of refined cannabis oils and distillates. Through MedMen dispensaries, Zoots Edibles are currently available in Washington and Colorado and will soon be on shelves at dispensaries in Massachusetts, New York and Pennsylvania.
  • Vuber Technologies hardware produces the best vaporization experience on the market.
  • Vegas M Stick vaporizer pens are distributed to stores in Washington State with plans to expand to Oregon and Nevada.
  • Vegas Valley Growers is a revenue-generating, vertically integrated operation in Las Vegas, Nevada, with a full complement of production, manufacturing and distribution licenses.

IONIC has also acquired two U.S. patents issued to Canna Café that are related to cannabinoid (CBD) infused coffee and CBD-infused coffee in a Keurig ® K-Cup ® Pod. An international patent is in process for cannabis-infused teas.

Experienced Management Team

IONIC Brands is led by an innovative product team, powerful sales organization and a world-class marketing group.

Chairman & CEO John Gorst has built and sold four different technology companies with market valuations in excess of $600 million. Gorst has been at the forefront of IONIC’s expansion and development into Washington state’s leading vaporizer brand.

Andrew Schell, President, Vice-Chairman & Co-Founder, has built several successful companies. Schell has an engineering background rounded in operations, strategy and corporate law, and most recently was CEO of a U.S. Department of Defense company specializing in military operations.

Christian Struzan, Chief Marketing Officer & Co-Founder, has over 30 years of experience in marketing and branding in the entertainment and consumer goods industries. Struzan founded an advertising agency which developed and executed marketing campaigns for feature films such as the Star Wars franchise, Fight Club, and the television series American Idol. He has also worked on global brands such as Guinness, Stella Artois and Beck’s.

Johnny Stange, Chief Revenue Officer, was formerly a director of sales for the southern California region for Treasury Wine Estates, a major wine wholesaler, where he grew and oversaw annual sales of $250 million. Stange is leading the charge in IONIC’s aggressive sales growth plans across multiple states.

In 2018, IONIC was voted one of the “Top 50 Companies to Work for in Cannabis” by MG Magazine, a publication serving cannabis industry professionals.

IONIC Brands Corp. (OTC: IONKF), closed Wednesday's trading session at $0.05, off by 17.3554%, on 702,291 volume with 99 trades. The average volume for the last 3 months is 235,156 and the stock's 52-week low/high is $0.035999998/$0.634559988.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint, Inc. (SING) was highlighted today in a publication from Investorideas.com, examining how, since Federal legalization in Canada, and with new markets opening up every day in either the US or abroad the cannabis industry has become a magnet for game changing technology growth-whether looking at production, extraction, online sales platforms, blockchain technology, packaging and so on, the list is endless.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Wednesday's trading session at $0.012, even for the day, on 1,855,406 volume with 84 trades. The average volume for the last 3 months is 5,472,019 and the stock's 52-week low/high is $0.0101/$0.041000001.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.